Profile data is unavailable for this security.
About the company
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
- Revenue in USD (TTM)983.71m
- Net income in USD-545.06m
- Incorporated1987
- Employees1.54k
- LocationNovavax Inc700 Quince Orchard RoadGAITHERSBURG 20878United StatesUSA
- Phone+1 (240) 268-2000
- Fax+1 (302) 636-5454
- Websitehttps://www.novavax.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Compass Pathways PLC (ADR) | 0.00 | -118.46m | 553.57m | 186.00 | -- | 2.22 | -- | -- | -2.39 | -2.39 | 0.00 | 3.64 | 0.00 | -- | -- | 0.00 | -50.06 | -40.85 | -54.08 | -44.48 | -- | -- | -- | -- | -- | -- | 0.113 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
Prime Medicine Inc | 0.00 | -198.13m | 563.71m | 234.00 | -- | 3.44 | -- | -- | -2.17 | -2.17 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -71.51 | -- | -84.13 | -- | -- | -- | -- | -- | -- | -85.97 | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
Mineralys Therapeutics Inc | 0.00 | -71.90m | 563.81m | 28.00 | -- | 1.94 | -- | -- | -1.79 | -1.79 | 0.00 | 5.86 | 0.00 | -- | -- | 0.00 | -39.28 | -- | -41.38 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
Olema Pharmaceuticals Inc | 0.00 | -96.66m | 567.53m | 74.00 | -- | 2.20 | -- | -- | -2.16 | -2.16 | 0.00 | 4.62 | 0.00 | -- | -- | 0.00 | -39.24 | -30.06 | -42.54 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
GH Research PLC | 0.00 | -35.59m | 576.47m | 49.00 | -- | 2.63 | -- | -- | -0.6841 | -0.6841 | 0.00 | 4.21 | 0.00 | -- | -- | 0.00 | -14.81 | -- | -15.16 | -- | -- | -- | -- | -- | -- | -- | 0.0044 | -- | -- | -- | -58.47 | -- | -- | -- |
Novavax Inc | 983.71m | -545.06m | 580.81m | 1.54k | -- | -- | -- | 0.5904 | -5.53 | -5.53 | 9.42 | -5.14 | 0.485 | 8.76 | 5.18 | 637,527.60 | -26.88 | -46.06 | -- | -269.57 | 65.10 | -- | -55.41 | -75.94 | 0.6741 | -38.31 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
Korro Bio Inc | 0.00 | -81.17m | 584.09m | 101.00 | -- | 2.97 | -- | -- | -68.38 | -68.38 | 0.00 | 21.20 | 0.00 | -- | -- | 0.00 | -47.34 | -31.55 | -53.69 | -36.48 | -- | -- | -- | -365.87 | -- | -- | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
Lyell Immunopharma Inc | 130.00k | -234.63m | 584.42m | 224.00 | -- | 0.8918 | -- | 4,495.55 | -0.9353 | -0.9353 | 0.0005 | 2.58 | 0.0002 | -- | -- | 580.36 | -27.81 | -- | -29.04 | -- | -- | -- | -180,486.20 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
Savara Inc | 0.00 | -54.70m | 585.75m | 37.00 | -- | 4.17 | -- | -- | -0.3424 | -0.3424 | 0.00 | 1.02 | 0.00 | -- | -- | 0.00 | -34.47 | -36.86 | -36.36 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.158 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
Aerovate Therapeutics Inc | 0.00 | -75.52m | 590.69m | 51.00 | -- | 5.38 | -- | -- | -2.87 | -2.87 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -57.49 | -- | -63.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
Mind Medicine (MindMed) Inc | 0.00 | -95.73m | 594.47m | 57.00 | -- | 4.45 | -- | -- | -2.45 | -2.45 | 0.00 | 1.90 | 0.00 | -- | -- | 0.00 | -65.01 | -- | -78.34 | -- | -- | -- | -- | -- | -- | -- | 0.1531 | -- | -- | -- | -68.55 | -- | -- | -- |
Zymeworks Inc | 76.01m | -118.67m | 603.36m | 272.00 | -- | 1.30 | -- | 7.94 | -1.74 | -1.74 | 1.10 | 6.57 | 0.1236 | -- | 2.88 | 279,455.90 | -19.30 | -22.58 | -22.01 | -26.90 | -- | -- | -156.13 | -91.17 | -- | -- | 0.0003 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
Cabaletta Bio Inc | 0.00 | -67.68m | 606.59m | 101.00 | -- | 2.62 | -- | -- | -1.65 | -1.65 | 0.00 | 4.94 | 0.00 | -- | -- | 0.00 | -36.52 | -33.76 | -39.22 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
Stoke Therapeutics Inc | 8.78m | -104.70m | 607.69m | 110.00 | -- | 3.36 | -- | 69.21 | -2.38 | -2.38 | 0.1996 | 3.47 | 0.0363 | -- | 26.94 | 79,827.27 | -43.23 | -31.62 | -49.60 | -33.92 | -- | -- | -1,192.34 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
Holder | Shares | % Held |
---|---|---|
SSgA Funds Management, Inc.as of 31 Dec 2023 | 16.78m | 11.99% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 14.30m | 10.22% |
Shah Capital Management, Inc.as of 10 Apr 2024 | 9.33m | 6.66% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 7.55m | 5.39% |
Morgan Stanley & Co. LLCas of 31 Dec 2023 | 7.16m | 5.12% |
Geode Capital Management LLCas of 31 Dec 2023 | 2.30m | 1.64% |
Rafferty Asset Management LLCas of 31 Dec 2023 | 1.61m | 1.15% |
Coatue Management LLCas of 31 Dec 2023 | 1.52m | 1.09% |
TSP Capital Management Group LLCas of 31 Dec 2023 | 1.11m | 0.79% |
Jane Street Capital LLCas of 31 Dec 2023 | 1.10m | 0.78% |